Contemporary review of the 532 nm laser for treatment of benign prostatic hyperplasia. Review uri icon

Overview

abstract

  • Benign prostatic hyperplasia (BPH) is a condition that occurs increasingly with age. The established gold standard treatment for BPH has been the electrocautery-based transurethral resection of the prostate (TURP). TURP, however, is associated with several complications and side effects. Therefore, there is an increasing interest in a number of emerging minimally invasive therapies as alterative treatment options. Laser therapy using the Greenlight laser is a promising alternative to the traditional TURP. Selective absorption by hemoglobin allows rapid, hemostatic vaporization of prostate tissue. Additional advantages include avoidance or minimization of complications such as intraoperative fluid absorption, and bleeding, retrograde ejaculation, impotence, and incontinence, as well as its use in treating high volume BPH. We review the use of the Greenlight laser in the treatment of BPH, when comparing complications and advantages in relation to TURP.

publication date

  • April 16, 2015

Identity

PubMed Central ID

  • PMC5730738

Scopus Document Identifier

  • 85027874714

Digital Object Identifier (DOI)

  • 10.1016/j.ajur.2015.04.021

PubMed ID

  • 29264127

Additional Document Info

volume

  • 2

issue

  • 2